In breast cancer patients with oligometastatic disease, what proportion progress at new sites of disease?
A molecular analysis of two nasopharyngeal cancer trials found that what proportion had a molecular profile that derived significant benefit from PD-1 blockade?
Do isolated tumor cells matter in patients with otherwise low risk endometrial cancer?
Answers
Nearly two thirds (or about 60%), which was seen in this retrospective study.
63% had intermediate metabolic activity with an immune-infiltrated but immunosuppressive microenvironment that derived a significant EFS benefit from anti-PD-1 therapy. In this group, 3-year EFS was 90.2% with PD-1 blockade vs 69.6% without in the CONTINUUM cohort and 92.5% vs 74.3% in the DIPPER cohort.
Yes according to this NCDB analysis that found worse OS when ITCs were present in regional nodes. | QuadShot News
A molecular analysis of two nasopharyngeal cancer trials found that what proportion had a molecular profile that derived significant benefit from PD-1 blockade?
Do isolated tumor cells matter in patients with otherwise low risk endometrial cancer?
Answers
Nearly two thirds (or about 60%), which was seen in this retrospective study.
63% had intermediate metabolic activity with an immune-infiltrated but immunosuppressive microenvironment that derived a significant EFS benefit from anti-PD-1 therapy. In this group, 3-year EFS was 90.2% with PD-1 blockade vs 69.6% without in the CONTINUUM cohort and 92.5% vs 74.3% in the DIPPER cohort.
Yes according to this NCDB analysis that found worse OS when ITCs were present in regional nodes. | QuadShot News